Kwame Zaire is a titan in the manufacturing world, renowned for bridging the gap between high-level production management and the intricate mechanics of biopharmaceutical supply chains. With a career dedicated to predictive maintenance and quality assurance, he has watched the industry shift from a capacity-first mindset to one defined by hyper-efficiency and technological integration. As biopharmaceutical companies increasingly lean on external partners to navigate the complexities of biologics and cell-line development, Kwame’s insights into operational “invisible economics” have become essential for leaders looking to survive a tightening market. Today, we discuss the shifting dynamics of the CDMO sector, the rising pressure of batch costs, and why traditional quality standards are no longer enough to win customer loyalty.
With the outsourced share of mammalian biologics manufacturing expected to exceed 50%, how are you seeing the relationship between biopharma firms and CDMOs evolve as they move toward larger 2,000-liter single-use bioreactor systems?
We are witnessing a truly pronounced shift in how the industry views external capacity, particularly as we hit that 50% threshold for both clinical and commercial supply. In the past, companies might have kept their most critical mammalian biologics in-house to maintain control, but the scale offered by 2,000-liter single-use bioreactors has made outsourcing an operational necessity. This transition means that CDMOs are no longer just “overflow” providers; they are now the backbone of the global supply chain for complex therapeutics. However, this deeper reliance brings a higher level of scrutiny, where biopharma leaders are looking for partners who can handle the sheer volume of 2,000-liter runs without sacrificing the delicate biological integrity of the product. It is a high-stakes environment where the partnership is defined less by a contract and more by the CDMO’s ability to integrate seamlessly into the client’s long-term commercial strategy.
Recent data suggests a surprising lack of customer loyalty in the sector, with very few providers receiving high advocacy scores. Why do you think so many mammalian expression system providers are seeing more detractors than promoters right now?
The reality is that customer loyalty in this sector is currently incredibly thin, and that stems from a gap between marketing promises and factory-floor reality. When you look at the numbers, it is jarring to see that in fill-finish services, only three of the top 15 providers are actually recommended by their customers. Even in cell-line development, we only see five out of 21 providers achieving a positive advocacy score, which tells me that the majority of clients feel their needs are being met with mediocrity rather than excellence. In mammalian expression systems, the situation is even more dire, with most providers having more detractors than promoters because they struggle with consistency. Clients are tired of the “bait and switch” where they are shown a shiny facility but experience delays and communication breakdowns once the project begins.
We’ve seen batch prices rise by 7% since 2020, and that trend isn’t slowing down. How can CDMOs balance the demand for lower costs when pricing has suddenly jumped to a primary selection criterion alongside speed and reliability?
The economic pressure is reaching a boiling point because that 7% increase in batch prices is hitting budgets at the same time that biopharma companies are tightening their belts. Cost has moved from being a secondary consideration to the primary factor in supplier selection, ranking right alongside reliability and speed. In fill-finish specifically, low cost is now the second most important factor in the entire buying decision, which puts CDMOs in a very difficult position. They cannot simply cut corners because the regulatory and quality standards are non-negotiable, so they have to find a way to offer competitive pricing through sheer operational brilliance. This means providers have to stop looking at pricing as a negotiation tactic and start looking at it as a reflection of their internal efficiency and ability to manage rising input costs.
You’ve often argued that physical square footage doesn’t matter if execution isn’t flawless. In an era where quality is a baseline requirement rather than a differentiator, what does “flawless operational performance” look like on the factory floor?
For a long time, CDMOs won business simply by having available space and being regulatory compliant, but that era is over. Today, “quality” is seen as the entry fee to the game—it is the baseline requirement, and if you can’t hit it, you shouldn’t even be in the conversation. Flawless operational performance means mastering the “invisible economics” of the facility, which are the tiny efficiencies and inefficiencies that never show up on an RFP but dictate the unit cost. It looks like a factory floor where the transition between batches is seamless, where equipment downtime is predicted and prevented, and where every staff member is synchronized to avoid the common pitfalls of manual errors. If a provider has a massive footprint but lacks this level of execution, they will ultimately lose out to smaller, more agile competitors who can guarantee a successful run every single time.
It’s striking that quality deviations and failed batches can account for 15% to 20% of the cost of goods sold. What specific strategies should manufacturers employ to eliminate this operational waste and reclaim that lost value?
When you realize that nearly a fifth of your costs are being swallowed by failed batches and rework, you start to see where the real competitive advantage lies. To reclaim that 15% to 20%, CDMOs must adopt a rigorous lean manufacturing approach that focuses on scrap reduction and maximizing yield at every single step. This isn’t just about cleaning up the floor; it’s about deep process analytical technologies that allow for precise control over drug development to catch deviations before they result in a lost batch. We need to eliminate utilization gaps where expensive bioreactors sit idle and tackle yield losses through better environmental controls and operator training. By focusing on these structural inefficiencies, a CDMO can lower its prices for the customer while actually increasing its own profit margins, creating a win-win scenario that is grounded in operational discipline.
How are tools like digital twins, AI, and advanced analytics moving from being “nice-to-haves” to essential components for managing deviations and optimizing yields?
We are at a point where AI and advanced analytics are becoming the primary tools for reducing planning variability and managing the complexities of bioprocessing. Digital twins, for instance, allow us to simulate manufacturing runs in a virtual environment, which significantly lowers the risk of contamination and allows us to test “what-if” scenarios without wasting expensive raw materials. These technologies are providing a level of control that was simply impossible a decade ago, enabling faster delivery timelines and far more manufacturing flexibility. As we look at the current landscape, the CDMOs that leverage AI to optimize their yields will have a structural cost advantage that their less-technical competitors simply won’t be able to match. It’s no longer about just following a recipe; it’s about using data to ensure that every variable is accounted for in real-time.
What is your forecast for the CDMO industry over the next few years?
My forecast is that we will see a dramatic “flight to quality” where the market consolidates around the few providers who can actually deliver on the promise of flawless execution. As batch prices continue to climb and biopharma reliance on these partners grows beyond the 50% mark, the providers who fail to improve their advocacy scores will find themselves phased out by more technologically advanced players. We will see the widespread adoption of continuous manufacturing and AI-driven process optimization becoming the industry standard rather than a niche capability. Ultimately, the successful CDMOs of the future won’t just be selling capacity; they will be selling reliability and cost-competitiveness backed by a level of transparency and data-driven precision that the industry has never seen before. Those who can master their internal economics will be the ones defining the next decade of biopharmaceutical innovation.
